Is it possible for a Green Tea extract to potentially alleviate fibrosis?

In a pioneering pilot study conducted by UC-San Francisco, a compelling connection has emerged between the potential reversal of fibrosis and the use of an over-the-counter supplement known as epigallocatechin gallate (EGCG). This natural, plant-derived compound is abundantly found in green tea and has been the focus of recent investigation due to its intriguing properties.

The study implemented a strategic approach, where half of the participating patients received capsules containing 600 mg of EGCG (Teavigo) on a daily basis for a duration of 14 days before undergoing biopsy. The remaining half, constituting the untreated group, did not receive the EGCG capsules. The biopsy results yielded a noteworthy outcome - the EGCG-treated patients exhibited lower levels of fibrotic markers in their lung tissue compared to a similar group that did not receive the supplement.

What makes this discovery particularly intriguing is the observation of decreased amounts of two fibroblast-derived serum biomarkers, namely cartilage oligomeric matrix protein and periostin. These specific biomarkers are typically unresponsive to drugs that have received approval from the Food and Drug Administration (FDA) for idiopathic pulmonary fibrosis (IPF) treatment. This unexpected decrease hints at a potential antifibrotic effect associated with EGCG treatment.

The study, while cautious about drawing definitive conclusions from these initial findings, suggests that this discovery could serve as a robust ethical foundation for the initiation of a more extensive and rigorous, randomized clinical trial. This proposed long-term investigation would specifically involve patients diagnosed with interstitial lung disease, aiming to provide deeper insights into the sustained reduction of fibrogenesis through prolonged EGCG treatment.

This groundbreaking research has been made possible through the generous support and funding from notable organizations such as Three Lakes Partners and the National Institutes of Health (NIH). These collaborative efforts underscore the commitment of various stakeholders to advancing the understanding and potential treatment options for pulmonary fibrosis.

In expressing our gratitude, we commend the investigators for their innovative approach and dedication to unraveling the complexities of IPF. Their work not only sheds light on a potential therapeutic avenue but also sets the stage for continued exploration and development in the field of pulmonary fibrosis research. As we await further developments, the implications of this study open doors to new possibilities in the pursuit of effective treatments for this challenging and often debilitating condition.